MedTrace Logo

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

NCT05590221 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-01-08

No results posted yet for this study

Summary

The primary objective of this study is to estimate the efficacy of Relmacabtagene Autoleucel in participants with high-risk large B-cell lymphoma.

Conditions

Interventions

BIOLOGICAL

Relmacabtagene Autoleucel

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

DRUG

Fludarabine

Administered according to package insert

DRUG

Cyclophosphamide

Administered according to package insert

Sponsors & Collaborators

  • Shanghai Ming Ju Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Yuqin Song, PhD · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-03
Primary Completion
2024-02-10
Completion
2024-12-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05590221 on ClinicalTrials.gov